Reduced Insulin-Like Growth Factor 1 Is Associated with Insulin Resistance in Obese Prepubertal Boys

Jiangying Kuang,1 Li Zhang,2 Yueqin Xu,2 Jiang Xue,3 Shuang Liang2,3 and Juan Xiao4

1Department of Cardiology, The Second Hospital, Chee1oo College of Medicine, Shandong University, China
2Child Health Care Center, The First Affiliated Hospital of Shandong First Medical University, China
3Department of Pediatrics, The Second Hospital, Chee1oo College of Medicine, Shandong University, China
4Center of Evidence-Based Medicine, Institute of Medical Sciences, The Second Hospital, Chee1oo College of Medicine, Shandong University, China

Correspondence should be addressed to Shuang Liang; liangshuang3508@163.com

Received 23 October 2020; Revised 22 June 2021; Accepted 13 August 2021; Published 25 August 2021

Academic Editor: Mark M. Kushnir

Copyright © 2021 Jiangying Kuang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

As one of the most common features of obesity, insulin resistance is central to the pathogenesis of the metabolic syndrome. Low insulin-like growth factor 1 (IGF-1) levels have been proven to be associated with many traditional cardiovascular risk factors, but it still remains controversial with the relationship between IGF-1 and insulin resistance. Accordingly, the main purpose of this study is to investigate the relationship between IGF-1 and insulin resistance in obese prepubertal boys. We used the whole-body insulin sensitivity index (WBISI) to represent insulin resistance. 70 obese prepubertal boys were included in the study, and the obese subjects were divided into two groups by using 1.285 as a threshold value for WBISI. Clinical examination and laboratory examinations were assessed for all participants. Among obese boys, the group of children with WBISI ≤ 1.285 had lower IGF-1 standard deviation scores (SDS) (p = 0.021) than the WBISI > 1.285 group. The results of multiple linear analyses show that lg WBISI was positively correlated with IGF-1 SDS (p = 0.031) after adjusting for traditional cardiovascular disease risk factors. IGF-1 SDS was negatively associated with insulin resistance in obese prepubertal boys, independent of other traditional cardiovascular disease risk markers.

1. Background

Childhood obesity has become a major health problem all over the world. It is not only an independent chronic metabolic disease but also an important risk factor for chronic diseases such as hypertension, hyperlipidemia, type 2 diabetes, and metabolic syndrome in children [1]. As the most common feature of childhood obesity, insulin resistance is critical to the pathogenesis of the metabolic syndrome. Several quantitative tools have been used to assess insulin sensitivity and insulin resistance [2], but there is still no consensus of standards in the pediatric population. Although hyperinsulinemic-euglycemic clamp and the frequently sampled intravenous glucose tolerance test were described as gold standard methods for assessing insulin resistance, it is impractical to be widely used in pediatric population due to its expensive and multiple blood drawn. The homeostatic model assessment index of insulin resistance (HOMA-IR), a simpler, less invasive method, has been widely used in children and adolescents; however, Shaibi et al. [3] showed that fasting indices are not recommended when studying the effect of interventions on insulin sensitivity in overweight youth. The whole-body insulin sensitivity index (WBISI) derived from an oral glucose tolerance test (OGTT) provides reasonable estimates of insulin sensitivity and insulin resistance and has been validated as good surrogate measures of insulin resistance in obese children and adolescents [4, 5].

Insulin-like growth factor 1 (IGF-1) is primarily produced in the liver upon stimulation by growth hormone (GH), and it plays key roles in regulating proliferation, differentiation, metabolism, and cell survival [6]. There were lots of accumulating evidences that obese children and
experimental animals were often accompanied with low IGF-1 levels [7, 8]. Moreover, low IGF-1 levels were independently associated with cardiovascular risk factors such as nonalcoholic fatty liver disease [9], low high-density lipoprotein cholesterol [7], and metabolic syndrome [7] in obese children. Nonetheless, it still remains controversial with the relationship between IGF-1 and insulin resistance. Furthermore, most previous studies used adults as main samples, and also, most of them just used HOMA-IR to represent insulin resistance. To the best of our knowledge, no study has ever used WBISI to represent insulin resistance to assess the relationship between IGF-1 and insulin resistance in children. To this end, this study is aimed at investigating the association between IGF-1 and WBISI in obese prepubertal boys.

2. Materials and Methods

2.1. Subjects. We recruited 70 obese prepubertal boys (age 7–12 years) who had been referred to the Department of Pediatrics, The Second Hospital, Cheeloo College of Medicine, Shandong University. The inclusion criteria: all subjects were obese (body mass index (BMI) > 95th percentile for the age and sex), but otherwise healthy. All participants were prepubertal boys. None had any syndrome or disease that could influence dietary intake and endocrine disorders. None had type 1 or 2 diabetes mellitus, serious infection, systemic disease, and other chronic wasting illnesses. None had short stature, or the growth velocity is less than 5 cm/year. None was taking medication that would influence body composition, GH secretion or blood pressure, glucose, or lipid metabolism, and no one has any nutritional and supplements intake.

Taking WBISI as the main variable, obese children were classified according to the median WBISI values to find the center value for this population of obese children. Thus, the obese children were divided into two groups: obese children with a WBISI ≤ median value and obese children with a WBISI > median value.

The Ethics Committee of The Second Hospital, Cheeloo College of Medicine, Shandong University approved the study. Written informed consent was obtained from all parents and subjects.

2.2. General Information and Anthropometric Measurements. General information includes family economic status and parents’ education level. We used parents’ monthly household income to represent family economic status. Monthly household income based on the following 3-point level: 1 ≤ ¥5000, 2 = ¥5001 ~ ¥10,000, and 3 ≥ ¥10,001 (¥ is the unit of RMB). Parents’ education level is based on the following 3-point level: 1 = college education not completed, 2 = completed college education, and 3 = completed graduate education. Body weight was determined to the nearest 0.1 kg on a standard electronic scale, and height was measured with a standard height stadiometer (TI-220S-18, Beideneng, Shanghai, China), to the nearest 0.1 cm. BMI was determined as weight/height² and expressed as kg/m². Body mass index standard deviation score (BMI-SDS) was calculated based on the age and sex reference values for Chinese children [10]. The pubertal stage is according to Tanner criteria [11]. Blood pressure was measured with an Audio Intelligent Electronic Sphygmomanometer (HEM-7071, OMRON, China) after a 30 min rest, in a supine position. Two measurements were made, and record the average of two measurements of systolic blood pressure (SBP) and diastolic blood pressure (DBP).

2.3. Laboratory Measurements. Fasting blood samples were collected from subjects after a 12 h overnight fast for measurement of endocrine indexes, glucose, lipid levels, and other metabolic factors. OGTT was performed. Plasma glucose and insulin values were assessed at time 0, 30, 60, 90, and 120 minutes after the consumption of an oral glucose solution (1.75 g/kg, maximum of 75 g). Free triiodothyronine (FT3), free thyroxine (FT4), thyroid-stimulating hormone (TSH), adrenal corticotropic hormone (ACTH), cortisol (COR), and IGF-1 were measured using chemiluminescence assay (Siemens Healthcare Diagnostics, USA). The intra- and interassay CVs were 5–9%. IGF-1 levels were transformed into IGF-1 SDS based on the age-gender-related normative references [12], and the intra- and interassay CVs were 4.5% and 7.7%, respectively. Total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), triglycerides (TG), fasting plasma glucose (FPG), C-reactive protein (CRP), and uric acid were detected by using an Auto Biochemical Analyzer (AU5400, Beckman Coulter, Tokyo, Japan). Fasting insulin was measured with chemiluminescent immunometric assays (CobasEI70, Roche Diagnostics, Mannheim, Germany). Plasma glycosylated hemoglobin (HbA1c) was measured using high-performance liquid chromatography (Tosoh Corporation, Tokyo, Japan). The intra-assay and interassay coefficients of variation were < 8.0%. Insulin resistance was estimated using WBISI. WBISI = 10,000/square root of (fasting glucose × fasting insulin (μIU/mL) × [mean glucose (mg/dL) × mean insulin during OGTT (μIU/mL)]) [13]. We also calculated other indicators for evaluating insulin sensitivity/resistance: HOMA-IR, homeostasis model assessment of β-cell function (HOMA-beta), and insulinogenic index (IGI). HOMA-IR is defined as fasting insulin (μIU/mL) × fasting glucose(mmol/L)/22.5. HOMA-beta is defined as fasting insulin (μIU/mL) × 20/[fasting glucose (mmol/L) − 3.5]. IGI = [30 minute insulin – fasting insulin (μIU/mL)]/[30 minute glucose – fasting glucose(mg/dL)].

Impaired fasting glucose (IFG) was defined as FPG ≥ 5.6 to 6.9 mmol/L. Impaired glucose tolerance (IGT) was defined as a 2 h blood glucose between 7.8 and 11.1 mmol/L [14]. The metabolic syndrome (MS) was defined as the presence of any three or more of the following five constituent risks according to the criteria of the International Diabetes Federation [15]: (1) abdominal obesity, (2) HDL-C < 1.03 mmol/L, (3) TG ≥ 1.7 mmol/L, (4) hypertension, (5) IFG.

2.4. Statistical Analysis. We used the Statistical Package for Social Sciences, version 20.0 (SPSS Inc. Chicago, USA) to analyze our data. The data were expressed as the mean (±
SD) of normally distributed or median (interquartile range) of skewed data. Data that were not normally distributed were transformed logarithmically for analysis. Differences in continuous variables between two groups were assessed by Student’s t-test for normally distributed data; variables which cannot be transformed to normal distribution were analyzed by the Mann-Whitney U test. The relationships among lg WBISI and other variables were evaluated based on the methods of Pearson’s correlation analysis or Spearman correlation analysis. Variables that achieved statistical significance in the univariate analysis (including IGF-1 SDS, lg insulin, and FBG) were subsequently included in a multiple linear regression model. A stepwise multiple linear regression analysis was performed to test the associations of lg WBISI (the dependent variable) with independent variables to determine whether the association between IGF-1 SDS and WBISI was independent of other markers. A p value of <0.05 was considered statistically significant.

3. Results

The median WBISI value for the population studied was 1.285. The data of the children with WBISI ≤ 1.285 (35 children) were compared with the data of the children with WBISI > 1.285 (35 children).

The characteristics of the anthropometric and clinical features are shown in Table 1. No significant differences were found in family economic status, parents’ education level, and age. BMI SDS was similar in the two groups. Blood pressure values and the incidence of FPG, IGT, and MS were the same in both groups.

In obese children, pituitary-thyroid axis, pituitary-adrenal axis, and IGF-1 have been performed. Endocrine factor findings of the obese children were stratified according to WBISI, which are shown also in Table 1. Notably, the group of children with WBISI ≤ 1.285 had lower IGF-1 SDS (p = 0.021). No significant differences were seen in the levels of FT3, FT4, TSH, ACTH, and COR in the two groups.

Table 1 also shows that the levels of cardiovascular metabolic risk factors of the obese children were stratified according to WBISI. No significant differences were seen in the levels of CRP, TC, HDL-C, LDL-C, TG, and uric acid between the two groups. In addition, there were no significant differences in FBG and HbA1c, whereas higher insulin levels, glucose 120 min, insulin 120 min, HOMA-IR, HOMA-beta, and IGI (all p < 0.001) were observed in the subjects with WBISI ≤ 1.285 than in children with WBISI > 1.285.

We performed a bivariate correlation analysis to explicit the relationship between lg WBISI and other variables in study population (Table 2). lg WBISI was positively associated with IGF-1 SDS (r = 0.358, p = 0.002) but was negatively associated with FBG (r = −0.394, p = 0.001) and lg insulin (r = −0.723, p < 0.001). However, lg WBISI were not significantly associated with other variables.

Univariate analysis showed that IGF-1 SDS, FBG, and lg insulin could be selected for the final equation. Furthermore, results from the multiple linear regression analysis showed that lg WBISI was positively correlated with IGF-1 SDS (p = 0.031) and was negatively correlated with lg insulin and FBG (p < 0.001, p = 0.006). The results of multiple regression analysis showed that IGF-1 SDS, lg insulin, and FBG were the independent determinant of lg WBISI in obese prepubertal boys after adjusting for other variables (shown in Table 3).

4. Discussion

Our study found that reduced IGF-1 were present in obese prepubertal boys with lower values of WBISI, which is a surrogate marker of insulin resistance. Furthermore, we provided evidences that WBISI was significantly correlated with IGF-1 SDS after controlling for other metabolic risk factors.

In the study, we confirmed a significant association between low levels of IGF-1 and insulin resistance in obese prepubertal boys. Moreover, the results of multiple regression analysis showed that independent correlation between insulin resistance is represented by WBISI and IGF-1 SDS after adjusting for other traditional cardiovascular disease risk markers. Based on the results, we can infer that the correlation between IGF-1 and traditional cardiovascular disease may be mediated by insulin resistance; thus, it represents a possible direction for a forthcoming research and therapeutic approach.

As we mentioned in the preface, several studies have evaluated the correlation between IGF-1 and insulin resistance in adults [16–21]. The results of most previous studies were consistent with our results [16–18, 20]. By contrast, a U-shaped curve [19] or no significant correlation [21] was noted between IGF-1 levels and insulin resistance in other studies. The possible reasons for these differences were that these studies reflect differences in study population and assess methods in insulin resistance. In our study, we choose WBISI to represent insulin resistance, which is considered to be a good surrogate measure of insulin resistance in obese children; it should have a certain scientific and clinical significance.

There is still not very clear about the precise underlying mechanisms of the correlation between IGF-1 and insulin resistance. The possible reasons of this correlation may be related to the following factors. Insulin and IGF-1 share structural homology, which interact with the same membrane receptors with different affinities to mediate a wide range of metabolic and growth-promoting functions. Studies have shown that insulin was likely to decrease IGF-1 through differential modulation of IGF-binding proteins [22]. This may be one mechanism for the link of IGF-1 and insulin resistance. Another possible explanation for the association between IGF-1 and insulin resistance is driven by chronic inflammatory. Low levels of IGF-1 in the C3H.6T mice [23] and in the liver-specific IGF-1 knockout mouse [22] were associated with enhanced inflammatory phenotype. On the contrary, elevated IGF-1 levels could attenuate the anti-inflammatory effects and the lowered oxidative stress [24–26]. Meanwhile, inflammatory factors and chronic inflammatory responses play an important role in the occurrence and development of insulin resistance [27].
In addition, macrophages may also be involved in the complex process of interaction between IGF-1 and insulin. Insulin has been considered to be proinflammatory in macrophages [28] and has been reported to promote foam cell formation [29]. By contrast, recent research showed that IGF-1 might have a fundamental role in macrophage activation [30, 31] and had the anti-inflammatory [31] and anti-foam cell formation [32] effects. Further studies are necessary to clarify specific mechanisms and effects of IGF-1 and insulin on macrophages.

This study also has several potential limitations. Firstly, we have not applied hyperinsulinemic-euglycemic clamp which is considered to be the gold standard for assessing insulin resistance. However, the clamp technique is invasive,

Table 1: Clinical characteristics in the two groups according to WBISI levels.

| Variable                  | WBISI ≤ 1.285 (n = 35) | WBISI > 1.285 (n = 35) | p value |
|---------------------------|-------------------------|------------------------|---------|
| Family economic status    |                         |                        |         |
| ≤¥5000/monthly           | 8/35                    | 11/35                  | 0.350   |
| ¥5001 – ¥10,000/monthly  | 18/35                   | 12/35                  |         |
| ≥¥10,001/monthly         | 9/35                    | 12/35                  |         |
| Maternal education       |                         |                        |         |
| <college                 | 6/35                    | 6/35                   | 0.291   |
| ≥college                 | 17/35                   | 17/35                  |         |
| ≥graduate                | 12/35                   | 12/35                  |         |
| Paternal education       |                         |                        | <      |
| <college                 | 8/35                    | 11/35                  |         |
| ≥college                 | 12/35                   | 12/35                  |         |
| ≥graduate                | 15/35                   | 12/35                  |         |
| Age (yr)                 | 11.18 ± 1.51            | 10.71 ± 2.09           | 0.291   |
| FPG                      | 11/35                   | 5/35                   | 0.077²  |
| IGT                      | 7/35                    | 3/35                   | 0.153²  |
| MS                       | 18/35                   | 16/35                  | 0.406²  |
| BMI SDS                  | 3.35 ± 0.91             | 3.12 ± 0.16            | 0.298   |
| SBP (mmHg)               | 125.57 ± 15.49          | 125.40 ± 13.57         | 0.961   |
| DBP (mmHg)               | 81.54 ± 11.74           | 78.14 ± 12.03          | 0.236   |
| IGF-1 SDS                | −1.08 ± 1.78            | −0.22 ± 1.25           | 0.021*  |
| FT3 (pmmol/L)            | 6.37 ± 0.96             | 6.07 ± 0.72            | 0.151   |
| FT4 (pmmol/L)            | 16.20 (14.67-17.34)     | 14.69 (12.24-16.72)    | 0.068   |
| TSH (μU/mL)              | 2.94 (1.87-3.42)        | 3.79 (2.02-5.40)       | 0.076²  |
| ACTH (mmol/L)            | 31.85 (17.47-49.24)     | 22.80 (16.46-39.29)    | 0.144²  |
| COR (pg/mL)              | 330.00 (264.30-534.00)  | 360.00 (241.00-453.00) | 0.539   |
| TC (mmol/L)              | 4.31 (3.77-4.68)        | 4.16 (3.56-4.67)       | 0.156   |
| HDL-C (mmol/L)           | 1.11 ± 0.21             | 1.12 ± 0.24            | 0.850   |
| LDL-C (mmol/L)           | 2.64 (2.26-2.99)        | 2.51 (16.46-39.29)     | 0.162   |
| TG (mmol/L)              | 1.39 (0.89-2.22)        | 1.30 (0.85-1.75)       | 0.557   |
| Uric acid (μmol/L)       | 422.49 ± 102.33         | 404.78 ± 131.30        | 0.531   |
| Insulin (μIU/mL)         | 52.17 (39.20-60.70)     | 17.40 (14.10-26.36)    | <0.001* |
| FBG (mmol/L)             | 5.24 ± 0.67             | 4.99 ± 0.47            | 0.078   |
| Glucose 120 min (mmol/L) | 6.97 (6.48-7.37)        | 6.11 (5.35-6.92)       | <0.001** |
| Insulin 120 min (μIU/mL) | 273.80 (193.90-475.90)  | 56.96 (20.91-136.10)   | <0.001* |
| HOMA-IR                  | 12.12 (8.12-14.06)      | 3.87 (3.12-6.05)       | <0.001* |
| HOMA-beta                | 673.00 (431.02-865.53)  | 252.79 (174.67-355.05) | <0.001* |
| HbA1c (%)                | 5.90 (5.70-6.30)        | 5.80 (5.50-6.00)       | 0.473   |
| IGI                      | 4.26 (3.01-6.37)        | 2.12 (1.38-3.28)       | <0.001* |
| CRP                      | 3.12 (1.07-4.61)        | 2.92 (1.14-5.68)       | 0.933   |

*Chi-square test or Mann-Whitney U test; *p < 0.05.
expensive, and not suitable for child clinical practice. Secondly, it is a cross-sectional study, so the causal relationship between IGF-1 and insulin resistance cannot be clarified.

Thirdly, another limitation of our research is that we lacked the normal control group, but parents cannot accept repeated blood tests on their healthy children. Failure to evaluate participants’ food intake and physical activity is another limitation of our research. Lastly, our sample was limited to Chinese obese prepubertal boys, but gender and pubertal developmental stage restriction can also reduce confounding factors. In spite of these limitations, to the best of our knowledge, this study is one of the first attempts to report the association between IGF-1 and WBISI in obese children; thus, it should have some implications for clinical practice. Our data suggested that the assessment of IGF-1, performing OGTT experiments, and calculating WBISI might provide useful clinical information on the severity and complications of obesity in children.

In conclusion, we have found a strong correlated relationship between low IGF-1 and insulin resistance in obese children and obesity-related complications.

### Abbreviations

- HOMA-IR: Homeostasis model assessment-insulin resistance
- OGTT: Oral glucose tolerance test
- WBISI: Whole-body insulin sensitivity index
- IGF-1: Insulin-like growth factor 1
- GH: Growth hormone
- BMI: Body mass index
- BMI SDS: Body mass index standard deviation scores
- SBP: Systolic blood pressure
- DBP: Diastolic blood pressure
- FT3: Free triiodothyronine
- FT4: Free thyroxine
- TSH: Thyroid-stimulating hormone
- ACTH: Adrenal corticotropic hormone
- COR: Cortisol
- TC: Total cholesterol
- HDL-C: High-density lipoprotein cholesterol
- LDL-C: Low-density lipoprotein cholesterol
- TG: Triglycerides
- FBG: Fasting blood glucose
- CRP: C-reactive protein
- Hba1C: Glycosylated hemoglobin
- HOMA-beta: Homeostasis model assessment of β-cell function
- IGI: Insulinogenic index
- IFG: Impaired fasting glucose
- IGT: Impaired glucose tolerance
- MS: Metabolic syndrome

### Data Availability

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

### Ethical Approval

The study protocol was approved by the Ethics Committee of The Second Hospital, Cheloo College of Medicine, Shan-dong University (No. KYLL-2017(LW)001).

### Consent

All the patients and their parents gave their written informed consent.

### Disclosure

A preprint has previously been published [33].

### Conflicts of Interest

The authors have no conflicts of interest to declare.
Authors’ Contributions

SL designed the study, performed the data analysis, and drafted the initial manuscript. JK critically reviewed and revised the manuscript. LZ, YX, and JX contributed significantly to the revision of the manuscript. JX participated in the work of statistical analysis. All authors read and approved the final manuscript.

Acknowledgments

This research was supported by the Jinan Clinical Medical Science and Technology Innovation Plan (No. 201907002), National Natural Science Foundation of China (No. 81800775), Doctoral Fund of Shandong Provincial Natural Science Foundation, China (ZR2018BH010), and Youth Fund of the Second Hospital of Shandong University (2018YT21). The authors are grateful to all children and their parents for participating in this study.

References

[1] A. C. Skinner, E. M. Perrin, L. A. Moss, and J. A. Skelton, “Cardiometabolic risks and severity of obesity in children and young adults,” The New England Journal of Medicine, vol. 373, no. 14, pp. 1307–1317, 2015.

[2] M. Gutch, S. Kumar, S. Razi, K. Gupta, and A. Gupta, “Assessment of insulin sensitivity/resistance,” Indian Journal of Endocrinology and Metabolism, vol. 19, no. 1, pp. 160–164, 2015.

[3] G. Q. Shabib, J. N. Davis, M. J. Weigensberg, and M. I. Goran, “Improving insulin resistance in obese youth: choose your measures wisely,” International Journal of Pediatric Obesity, vol. 6, no. 2-2, pp. e290–e296, 2011.

[4] P. C. Brar, D. Koren, P. R. Gallagher, B. Pendurthi, and L. E. Katz, “Comparison of oral and intravenous glucose tolerance test derived sensitivity and secretory indices in obese adolescents,” Clinical Pediatrics (Philadelphia), vol. 52, no. 3, pp. 247–253, 2013.

[5] C. W. Yeckel, R. Weiss, J. Dziura et al., “Validation of insulin sensitivity indices from oral glucose tolerance test parameters in obese children and adolescents,” The Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 3, pp. 1096–1101, 2004.

[6] R. Troncoso, C. Ibarra, J. M. Vicencio, E. Jaimovich, and S. Lavandero, “New insights into IGF-1 signaling in the heart,” Trends in Endocrinology and Metabolism, vol. 25, no. 3, pp. 128–137, 2014.

[7] S. Liang, Y. Hu, C. Liu, J. Qi, and G. Li, “Low insulin-like growth factor I is associated with low high-density lipoprotein cholesterol and metabolic syndrome in Chinese non-diabetic obese children and adolescents: a cross-sectional study,” Lipids in Health and Disease, vol. 15, no. 1, p. 112, 2016.

[8] J. Ren and P. Anversa, “The insulin-like growth factor I system: physiological and pathophysiological implication in cardiovascular diseases associated with metabolic syndrome,” Biochemical Pharmacology, vol. 93, no. 4, pp. 409–417, 2015.

[9] S. Liang, X. Cheng, Y. Hu, R. Song, and G. Li, “Insulin-like growth factor I and metabolic parameters are associated with nonalcoholic fatty liver disease in obese children and adolescents,” Acta Paediatrica, vol. 106, no. 2, pp. 298–303, 2017.

[10] H. Li, C. Y. Ji, X. N. Zong, and Y. Q. Zhang, “Height and weight standardized growth charts for Chinese children and adolescents aged 0 to 18 years,” Zhonghua er ke za zhi = Chinese Journal of Pediatrics, vol. 47, pp. 487–492, 2009.

[11] J. M. Tanner and R. H. Whitehouse, “Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty,” Archives of Disease in Childhood, vol. 51, no. 3, pp. 170–179, 1976.

[12] T. Isojima, A. Shimatsu, S. Yokoya et al., “Standardized centile curves and reference intervals of serum insulin-like growth factor-I (IGF-I) levels in a normal Japanese population using the LMS method,” Endocrine Journal, vol. 59, no. 9, pp. 771–780, 2012.

[13] M. Matsuda and R. A. Defronzo, “Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp,” Diabetes Care, vol. 22, no. 9, pp. 1462–1470, 1999.

[14] American Diabetes Association,”2. Classification and diagnosis of Diabetes:Standards of Medical Care in Diabetes-2021,” Diabetes Care, vol. 44, Supplement 1, pp. S15–S33, 2021.

[15] P. Zimmet, K. G. M. Alberti, F. Kaufman et al., “The metabolic syndrome in children and adolescents? an IDF consensus report,” Pediatric Diabetes, vol. 8, no. 5, pp. 299–306, 2007.

[16] G. C. Mannino, A. Greco, C. de Lorenzo et al., “A fasting insulin–raising allele at IGF1 locus is associated with circulating levels of IGF-1 and insulin sensitivity,” PLoS One, vol. 8, no. 12, article e85483, 2013.

[17] S. Teppala and A. Shankar, “Association between serum IGF-1 and diabetes among U.S. adults,” Diabetes Care, vol. 33, pp. 2257–2259, 2010.

[18] C. S. Lam, M. H. Chen, S. M. Lacey et al., “Circulating insulin-like growth factor-1 and its binding protein-3: metabolic and genetic correlates in the community,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 7, pp. 1479–1484, 2010.

[19] N. Friedrich, B. Thuesen, T. Jørgensen et al., “The association between IGF-I and insulin resistance: a general population study in Danish adults,” Diabetes Care, vol. 35, no. 4, pp. 768–773, 2012.

[20] X. Song, J. Teng, A. Wang, X. Li, J. Wang, and Y. Liu, “Positive correlation between serum IGF-1 and HDL-C in type 2 diabetes mellitus,” Diabetes Research and Clinical Practice, vol. 118, pp. 44–49, 2016.

[21] M. S. Mallea-Gil, M. C. Ballarino, A. Spirauquis et al., “IGF-1 levels in different stages of liver steatosis and its association with metabolic syndrome,” Acta gastroenterologica Latinoamericana, vol. 42, no. 1, pp. 20–26, 2012.

[22] A. O. Akanji and R. J. Smith, “The insulin-like growth factor system, metabolic syndrome, and cardiovascular disease risk,” Metabolic Syndrome and Related Disorders, vol. 10, no. 1, pp. 3–13, 2012.

[23] S. Y. Shai, S. Sukhanov, Y. Higashi, C. Vaughan, C. J. Rosen, and P. Delafontaine, “Low circulating insulin-like growth factor I increases atherosclerosis in ApoE-deficient mice,” American Journal of Physiology. Heart and Circulatory Physiology, vol. 300, no. 5, pp. H1898–H1906, 2011.

[24] T. Sivasubramaniam, S. A. Schroer, A. Li et al., “Hepatic JAK2 protects against atherosclerosis through circulating IGF-1,” JCI Insight, vol. 2, no. 14, 2017.

[25] S. Sukhanov, Y. Higashi, S. Y. Shai et al., “Differential requirement for nitric oxide in IGF-1-induced anti-apoptotic, anti-
oxidant and anti-atherosclerotic effects,” *FEBS Letters*, vol. 585, no. 19, pp. 3065–3072, 2011.

[26] M. G. Jeschke, R. E. Barrow, and D. N. Herndon, “Insulin-like growth factor I plus insulin-like growth factor binding protein 3 attenuates the proinflammatory acute phase response in severely burned children,” *Annals of Surgery*, vol. 231, no. 2, pp. 246–252, 2000.

[27] S. E. Shoelson, L. Herrero, and A. Naaz, “Obesity, inflammation, and insulin resistance,” *Gastroenterology*, vol. 132, no. 6, pp. 2169–2180, 2007.

[28] J. Manowsky, R. G. Camargo, A. P. Kipp, J. Henkel, and G. P. Püschel, “Insulin-induced cytokine production in macrophages causes insulin resistance in hepatocytes,” *American Journal of Physiology. Endocrinology and Metabolism*, vol. 310, no. 11, pp. E938–E946, 2016.

[29] Y. M. Park, S. R Kashyap, J. A Major, and R. L. Silverstein, “Insulin promotes macrophage foam cell formation: potential implications in diabetes-related atherosclerosis,” *Laboratory Investigation*, vol. 92, no. 8, pp. 1171–1180, 2012.

[30] Y. Higashi, S. Sukhanov, S.-Y. Shai et al., “Insulin-like growth factor-1 receptor deficiency in macrophages accelerates atherosclerosis and induces an unstable plaque phenotype in apolipoprotein E-deficient mice,” *Circulation*, vol. 133, no. 23, pp. 2263–2278, 2016.

[31] Y. Higashi, S. Gautam, P. Delafontaine, and S. Sukhanov, “IGF-1 and cardiovascular disease,” *Growth Hormone & IGF Research*, vol. 45, pp. 6–16, 2019.

[32] S. Sukhanov, P. Snarski, C. Vaughn et al., “Insulin-like growth factor I reduces lipid oxidation and foam cell formation via downregulation of 12/15-lipoxygenase,” *Atherosclerosis*, vol. 238, no. 2, pp. 313–320, 2015.

[33] J. Kuang, L. Zhang, Y. Xu, J. Xue, and S. Liang, “Association between insulin-like growth factor 1 and insulin resistance in obese prepubertal boys: a cross-sectional study,” 2020.

7BioMed Research International